Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
Excessive intake of dietary fat contributes to the development and maintenance of both obesity and hyperlipidemia. Inhibition of gastrointestinal lipases could decrease the amount of ingested fat that is absorbed systemically by preventing the hydrolysis of triglycerides. Ro 18-0647, a chemically synthesized derivative of the natural product lipstatin, inhibits the action of gastrointestinal lipases. Initial studies in humans have shown that Ro 18-0647 can reliably increase fecal fat excretion. Ro 18-0647 has also been shown to be well tolerated in the majority of normal volunteers and obese patients studied. Further research must be conducted to determine whether clinical endpoints of weight loss or cholesterol lowering can be produced by using this new pharmacologic principle.
Hauptman
J B
JB
Hoffmann-La Roche Inc, Nutley, NJ 07110-1199.
Jeunet
F S
FS
Hartmann
D
D
D004041:Dietary Fats / Q000378:metabolism; D005243:Feces; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors*; D000077403:Orlistat
D004041:Dietary Fats; D007783:Lactones; D000077403:Orlistat; D008049:Lipase